Yuxiang Ma

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

Wenfeng Fang, Yunpeng Yang, Yuxiang Ma et al. · The Lancet Oncology · 2018 · 495 citations

Medicine, Immunology, Pathology +8

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

Wenfeng Fang, Jianwei Zhang, Shaodong Hong et al. · Oncotarget · 2014 · 382 citations · Full text

Immunology, Immune Regulation, Cell Death +22

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer

Wenfeng Fang, Yuxiang Ma, Jiani C. Yin et al. · Clinical Cancer Research · 2019 · 235 citations

Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer

Sheng Jin, Wenfeng Fang, Juan Yu et al. · Scientific Reports · 2016 · 200 citations · Full text

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

Xuanye Zhang, Yixin Zhou, Chen Chen et al. · Journal for ImmunoTherapy of Cancer · 2019 · 175 citations · Full text